These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

572 related items for PubMed ID: 19483410

  • 1. [B cell targeting therapy using the anti-CD20 antibody in autoimmune diseases].
    Tanaka Y.
    Yakugaku Zasshi; 2009 Jun; 129(6):675-9. PubMed ID: 19483410
    [Abstract] [Full Text] [Related]

  • 2. Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab.
    Tokunaga M, Fujii K, Saito K, Nakayamada S, Tsujimura S, Nawata M, Tanaka Y.
    Rheumatology (Oxford); 2005 Feb; 44(2):176-82. PubMed ID: 15494350
    [Abstract] [Full Text] [Related]

  • 3. Treatment of inflammatory immunologic disease 4. B cell targeting therapy using the anti-CD20 antibody rituximab in inflammatory autoimmune diseases.
    Tanaka Y.
    Intern Med; 2007 Feb; 46(16):1313-5. PubMed ID: 17704614
    [No Abstract] [Full Text] [Related]

  • 4. Anti-CD20 monoclonal antibody in rheumatoid arthritis and systemic lupus erythematosus.
    Goldblatt F, Isenberg DA.
    Handb Exp Pharmacol; 2008 Feb; (181):163-81. PubMed ID: 18071946
    [Abstract] [Full Text] [Related]

  • 5. B-cell depletion and repopulation in autoimmune diseases.
    Pers JO, Daridon C, Bendaoud B, Devauchelle V, Berthou C, Saraux A, Youinou P.
    Clin Rev Allergy Immunol; 2008 Feb; 34(1):50-5. PubMed ID: 18270858
    [Abstract] [Full Text] [Related]

  • 6. B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus.
    Eisenberg R, Albert D.
    Nat Clin Pract Rheumatol; 2006 Jan; 2(1):20-7. PubMed ID: 16932648
    [Abstract] [Full Text] [Related]

  • 7. B cells as a therapeutic target in autoimmune diseases other than rheumatoid arthritis.
    Looney RJ.
    Rheumatology (Oxford); 2005 May; 44 Suppl 2():ii13-ii17. PubMed ID: 15851522
    [Abstract] [Full Text] [Related]

  • 8. B cell depletion in autoimmune disease.
    Gorman C, Leandro M, Isenberg D.
    Arthritis Res Ther; 2003 May; 5 Suppl 4(Suppl 4):S17-21. PubMed ID: 15180893
    [Abstract] [Full Text] [Related]

  • 9. Targeting B cells in SLE: the experience with rituximab treatment (anti-CD20).
    Eisenberg R.
    Endocr Metab Immune Disord Drug Targets; 2006 Dec; 6(4):345-50. PubMed ID: 17214580
    [Abstract] [Full Text] [Related]

  • 10. B-cell-targeted therapy for systemic lupus erythematosus.
    Sabahi R, Anolik JH.
    Drugs; 2006 Dec; 66(15):1933-48. PubMed ID: 17100405
    [Abstract] [Full Text] [Related]

  • 11. [Progress in B-cell targeting therapy for the treatment of systemic lupus erythematosus].
    Tanaka Y.
    J UOEH; 2011 Jun 01; 33(2):173-81. PubMed ID: 21702122
    [Abstract] [Full Text] [Related]

  • 12. [Anti-CD20 antibody therapy for inflammatory immune diseases].
    Tanaka Y.
    Nihon Naika Gakkai Zasshi; 2006 Sep 10; 95(9):1801-6. PubMed ID: 17037318
    [No Abstract] [Full Text] [Related]

  • 13. Perspectives of ofatumumab as CD20 targeted therapy in rheumatoid arthritis and other autoimmune diseases.
    Pers YM, Jorgensen C.
    Immunotherapy; 2016 Sep 10; 8(9):1091-6. PubMed ID: 27485081
    [Abstract] [Full Text] [Related]

  • 14. Anti-CD20 therapy and autoimmune disease: therapeutic opportunities and evolving insights.
    Silverman GJ.
    Front Biosci; 2007 Jan 01; 12():2194-206. PubMed ID: 17127456
    [Abstract] [Full Text] [Related]

  • 15. [CD20 antibody for the treatment of systemic autoimmune diseases].
    Tanaka Y.
    Nihon Rinsho; 2005 May 01; 63 Suppl 5():728-33. PubMed ID: 15954437
    [No Abstract] [Full Text] [Related]

  • 16. Should rituximab be considered as the first-choice treatment for severe autoimmune rheumatic diseases?
    Galarza C, Valencia D, Tobón GJ, Zurita L, Mantilla RD, Pineda-Tamayo R, Rojas-Villarraga A, Rueda JC, Anaya JM.
    Clin Rev Allergy Immunol; 2008 Feb 01; 34(1):124-8. PubMed ID: 18270866
    [Abstract] [Full Text] [Related]

  • 17. [Targeting CD20 in rheumatoid arthritis].
    Saito K, Tanaka Y.
    Nihon Rinsho; 2007 Jul 01; 65(7):1243-9. PubMed ID: 17642239
    [Abstract] [Full Text] [Related]

  • 18. Translational Mini-Review Series on B Cell-Directed Therapies: Recent advances in B cell-directed biological therapies for autoimmune disorders.
    Levesque MC.
    Clin Exp Immunol; 2009 Aug 01; 157(2):198-208. PubMed ID: 19604259
    [Abstract] [Full Text] [Related]

  • 19. Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of SBI-087, a CD20-Directed B-cell Depleting Agent: Phase 1 Dose Escalating Studies in Patients With Either Mild Rheumatoid Arthritis or Systemic Lupus.
    Cohen S, Clowse M, Pardo P, Bhattacharya I, Menon S, Gourley I, Diehl A.
    Clin Ther; 2016 Jun 01; 38(6):1417-1434.e2. PubMed ID: 27112532
    [Abstract] [Full Text] [Related]

  • 20. SLE - Rituximab in lupus.
    Eisenberg R.
    Arthritis Res Ther; 2003 Jun 01; 5(4):157-9. PubMed ID: 12823844
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.